Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05708092 · ClinicalTrials.gov registry record · NA

NRF for Improved Re-Entry Outcomes for Offenders With Brain Injury (Brain Injury RE)

A NA study of Brain Injury, sponsored by Icahn School of Medicine at Mount Sinai.

Active
Registry status
NA
Development phase
1,022
Enrollment target
2
Study locations

NCT05708092 is a NA study of Brain Injury that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 1,022 participants, below the 5,088-participant average among 10 other Brain Injury trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05708092, a NA study of Brain Injury, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,022 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness of NeuroResource Facilitation, a novel/innovative intervention, in reducing recidivism in offenders with brain injury (BI).

Conditions Studied

Interventions

  • BEHAVIORAL NeuroResource Facilitation (NRF)

Study Locations (2)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Pennsylvania

  • Brain Injury Association of Pennsylvania - Carlisle

Trial Details

FieldValue
Enrollment Target 1,022 participants
Start Date 2022-03-22
Est. Completion 2026-12-31
Phase NA

What the Registry Record Tells You About NCT05708092

The ClinicalTrials.gov registry entry for NCT05708092 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,022 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,088-participant average among 10 other Brain Injury trials with a reported enrollment target (80% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which NeuroResource Facilitation (NRF) is the first listed.

NCT05708092 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05708092 about?

NCT05708092 is a clinical study titled "NRF for Improved Re-Entry Outcomes for Offenders With Brain Injury (Brain Injury RE)". The purpose of this study is to evaluate the effectiveness of NeuroResource Facilitation, a novel/innovative intervention, in reducing recidivism in offenders with brain injury (BI).

What is the current status of trial NCT05708092?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,022 participants. The study started on 2022-03-22. Estimated completion is 2026-12-31.

What conditions does trial NCT05708092 study?

This clinical trial studies the following conditions: Brain Injury.

What interventions are being tested in trial NCT05708092?

The interventions under investigation include: NeuroResource Facilitation (NRF) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05708092?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05708092 being conducted?

This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.